(ARJO-B) Arjo (publ) - Ratings and Ratios
Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0010468116
ARJO-B: Medical Devices, Beds, Hygiene Products, Diagnostic Equipment
Arjo AB (publ) stands as a global leader in medical devices, dedicated to enhancing clinical outcomes and financial efficiency for healthcare providers. With operations spanning Europe, Asia-Pacific, South America, Africa, and international markets, Arjos reach is both broad and impactful. Their expertise lies in patient handling and wound care, offering solutions that improve patient mobility and prevent complications such as pressure injuries and deep vein thrombosis.
The companys diverse product portfolio includes medical beds, hygiene solutions, and diagnostics, catering to specialized needs like bariatric and dementia care. Their services extend beyond equipment, encompassing maintenance, rental, and financing options, which add significant value to their clients. This comprehensive approach underscores their commitment to holistic healthcare solutions.
Arjo serves both private and public healthcare institutions, addressing the needs of acute and long-term care settings. Their customer-centric model is built on a deep understanding of healthcare challenges, ensuring their offerings are tailored to meet the evolving demands of the medical field. By focusing on innovation and sustainability, Arjo continues to strengthen its market position and drive growth.
From a financial standpoint, Arjo AB presents a compelling profile for investors. With a market capitalization of 10,840.33M SEK, the company demonstrates stability and growth potential. Key financial metrics include a P/E ratio of 21.75 and a forward P/E of 14.03, indicating a valuation that aligns with market expectations. The price-to-book ratio of 1.26 and price-to-sales ratio of 0.97 further highlight its attractive position in the market.
Headquartered in Malmö, Sweden, Arjo AB has a legacy dating back to 1957, reflecting a history of reliability and innovation. Their strategic focus on R&D and sustainable practices
Additional Sources for ARJO-B Stock
ARJO-B Stock Overview
| Market Cap in USD | 1,011m |
| Sector | Healthcare |
| Industry | Medical Distribution |
| GiC Sub-Industry | Health Care Distributors |
| IPO / Inception |
ARJO-B Stock Ratings
| Growth 5y | -35.9% |
| Fundamental | 49.6% |
| Dividend | 37.9% |
| Rel. Strength Industry | -21.1 |
| Analysts | - |
| Fair Price Momentum | 37.63 SEK |
| Fair Price DCF | 101.37 SEK |
ARJO-B Dividends
| Dividend Yield 12m | 2.26% |
| Yield on Cost 5y | 2.34% |
| Annual Growth 5y | -7.09% |
| Payout Consistency | 92.0% |
ARJO-B Growth Ratios
| Growth Correlation 3m | 77.6% |
| Growth Correlation 12m | -81.8% |
| Growth Correlation 5y | -64.7% |
| CAGR 5y | 0.13% |
| CAGR/Max DD 5y | 0.00 |
| Sharpe Ratio 12m | -0.59 |
| Alpha | -26.61 |
| Beta | 0.26 |
| Volatility | 33.15% |
| Current Volume | 356k |
| Average Volume 20d | 383.6k |
As of March 16, 2025, the stock is trading at SEK 38.68 with a total of 356,002 shares traded.
Over the past week, the price has changed by +2.06%, over one month by -5.10%, over three months by +13.56% and over the past year by -20.37%.
Partly, yes. Based on ValueRay Fundamental Analyses, Arjo (publ) (ST:ARJO-B) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 49.58 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARJO-B as of March 2025 is 37.63. This means that ARJO-B is currently overvalued and has a potential downside of -2.71%.
Arjo (publ) has no consensus analysts rating.
According to ValueRays Forecast Model, ARJO-B Arjo (publ) will be worth about 40.9 in March 2026. The stock is currently trading at 38.68. This means that the stock has a potential upside of +5.84%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 42.6 | 10.1% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 40.9 | 5.8% |